Eiger Announces Abstract and Presentation at 2017 Digestive Disease Week in Chicago


Accepted DDW abstract is listed below:

- **Martins, EB and Glenn, JS; “Prevalence of Hepatitis Delta Virus (HDV) Infection in the United States: Results from an ICD-10 Review”; Abstract #2683218, Poster Presentation, May 6, 12:00 pm, South Hall (McCormick Place)**

**About Hepatitis Delta Virus (HDV)**

Hepatitis Delta (or Hepatitis D) is caused by infection with HDV and is considered to be one of the most severe forms of viral hepatitis in humans. Hepatitis delta occurs only as a co-infection in individuals harboring the Hepatitis B Virus (HBV). Hepatitis delta leads to more severe liver disease than HBV alone and is associated with accelerated liver fibrosis, liver cancer, and liver failure. Hepatitis delta is a disease with a significant impact on global health, which may affect up to approximately 15-20 million people worldwide. The prevalence of HDV varies among different parts of the world. Globally, HDV infection is reported to be present in approximately 4.3% to 5.7% of chronic Hepatitis B carriers. The prevalence of HDV in patients infected with chronic HBV is even higher in certain regions, including certain parts of Mongolia, China, Russia, Central Asia, Pakistan, Turkey, Africa, and South America, with an HDV prevalence as high as 60% being reported in HBV-infected patients in Mongolia and Pakistan.

**About Eiger**

Eiger is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare diseases. The company has built a diverse portfolio of well-characterized product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which an effective therapy is urgently needed.

Investors: Ingrid Choong, Eiger BioPharmaceuticals, 650-619-6115, ichoong@eigerbio.com